Abstract
Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) are increasingly used in the management of type 2 diabetes due to their cardiovascular, renal and metabolic benefits. Euglycemic diabetic ketoacidosis (DKA) is an unusual but well documented complication of SGLT-2i use. We present a case that expands the need of awareness of this metabolic complication among health providers to include the high risk of DKA relapse that occurs in the acute setting when patients have a recent history of SGLT2i use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
